Complications infectieuses dans la transplantation pulmonaire et coeur-poumons [Infectious complications of lung and heart-lung transplantation]

Détails

ID Serval
serval:BIB_CF89DC020E5C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Complications infectieuses dans la transplantation pulmonaire et coeur-poumons [Infectious complications of lung and heart-lung transplantation]
Périodique
Revue des Maladies Respiratoires
Auteur⸱e⸱s
Nicod L.P.
ISSN
0761-8425[print], 0761-8425[linking]
Statut éditorial
Publié
Date de publication
1996
Volume
13
Numéro
5 Suppl
Pages
S41-S47
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Thanks to a simplification of surgical techniques, single or double lung transplants have expanded significantly in latter years. Infection remains an important cause for morbidity and mortality, more so in early rather than late stages. Bacterial infections cause approximately fifty per cent of all infections. They can be prevented in part by prophylaxis. Infections to CMV have become less frequent thanks to adequate prophylaxis with ganciclovir. Herpetic infections are prevented by acyclovir or ganciclovir. A better control of immunosuppression seems to be associated with fewer lymphoproliferative disorders secondary to the Epstein-Barr virus. Respiratory viruses remain a serious threat for these patients, although infections due to respiratory syncitial virus may be attenuated by ribavirine. Fungal infections are dangerous but prophylactic prescription of azole derivatives have reduced the incidence and severity. Prophylaxis of infections to Pneumocystis carinii is essential, the use of sulfamethoxazole trimethoprim is efficacious against this as well as nocardiosis. Infections to Mycobacterium tuberculosis are often atypical and should be looked for and anticipated whenever possible.
Mots-clé
Acyclovir/therapeutic use, Antibiotic Prophylaxis, Antifungal Agents/therapeutic use, Antiviral Agents/therapeutic use, Bacterial Infections/prevention & control, Chemoprevention, Cytomegalovirus Infections/prevention & control, Ganciclovir/therapeutic use, Graft Survival, Heart-Lung Transplantation/adverse effects, Herpesviridae Infections/prevention & control, Herpesvirus 4, Human, Humans, Immunosuppression, Lung Transplantation/adverse effects, Lymphoproliferative Disorders/prevention & control, Lymphoproliferative Disorders/virology, Mycobacterium Infections, Atypical/prevention & control, Nocardia Infections/prevention & control, Pneumonia, Pneumocystis/prevention & control, Respiratory Syncytial Virus Infections/prevention & control, Ribavirin/therapeutic use, Survival Rate, Trimethoprim-Sulfamethoxazole Combination/therapeutic use, Tuberculosis, Pulmonary/prevention & control, Tumor Virus Infections/prevention & control, Virus Diseases/prevention & control
Pubmed
Web of science
Création de la notice
23/02/2010 16:00
Dernière modification de la notice
20/08/2019 16:49
Données d'usage